Biogen Announces $5.6 Billion Takeover of Apellis, Expanding Rare‑Disease Portfolio
🎧 Listen:By Connor Hart | March 31, 2026Biogen’s $5.6 B Acquisition of Apellis Aims to Supercharge Rare‑Disease Innovation Deal value of ...
Tag: Complement Inhibitors